Comparison of Therapeutic Efficacy of Ferrous Ascorbate and Iron Polymaltose Complex in Iron Deficiency Anemia in Children: A Randomized Controlled Trial
- 21 Downloads
To compare the therapeutic efficacy of Ferrous ascorbate (FA) and Iron polymaltose complex (IPC) in Iron deficiency anemia (IDA) in children.
A randomized controlled trial (RCT) was conducted at a tertiary care hospital with 125 (1–12 y) children having clinical symptoms and signs of IDA. Participants were randomized into FA group and IPC group. Both the groups received iron salts (FA or IPC) randomly in a dose of 6 mg/kg elemental iron for 3 mo and followed up on day 3, day 7, at the end of 1 mo and 3 mo for Hemoglobin (Hb), Mean corpuscular volume (MCV), Red cell distribution width (RDW) and reticulocyte count.
Both groups had an improvement in hematological parameters at 3 mo of intervention. The difference in the rise of Hb (g%) at the end of 1 mo in FA group (3.13 ± 1.01) vs. IPC group (2.0 ± 0.85); p = 0.017 and at 3 mo in FA group (4.88 ± 1.28) vs. IPC group (3.33 ± 1.33); p = 0.001 was statistically significant. The difference in the rise of mean Hb was significantly better in FA than the IPC group F  =1.79; p = 0.00 (ANOVA). The difference in the mean increase in MCV (fL) at day 7 in FA group (6.71 ± 8.32) vs. IPC group (2.91 ± 6.16); p = 0.011 and at 1 mo FA group (9.80 ± 8.56) vs. IPC group (5.35 ± 6.11); p = 0.004 was statistically significant. The mean decrease in RDW (%) at 1 mo in FA group (4.23 ± 3.27) vs. IPC group (2.67 ± 1.95); p = 0.005 and at 3 mo in FA group (5.74 ± 3.63) vs. IPC group (4.04 ± 2.17); p = 0.006 was statistically significant. The difference in the rise in mean reticulocyte count at day 3 in FA group (0.88 ± 0.50) vs. IPC group (0.43 ± 1.20); p = 0.017 and at day 7 in FA group (4.00 ± 1.69) vs. IPC group (2.19 ± 1.24); p = 0.001 was statistically significant. F  = 29.2, p = 0.00 (ANOVA). During the study period, the FA group had minor adverse reactions whereas the IPC group had none.
Both the iron salts (FA and IPC) used in the treatment of IDA showed statistically significant improvement in the hematological parameters during the 3 mo of intervention. The improvement in hematological parameters was better in FA supplemented patients as compared to IPC.
KeywordsIron deficiency anemia Ferrous ascorbate Iron polymaltose complex Comparison of ferrous ascorbate and iron polymaltose complex
PP and PG: Conceptualized and designed the study, designed data collection instruments, collected data, carried out initial analyses, drafted the initial manuscript, and approved the final manuscript as submitted. PK, TJ, AS, SM, SP and AF carried out the further analyses, reviewed and revised the manuscript, and approved the final manuscript as submitted. PP is the guarantor for this paper.
Compliance with Ethical Standards
Conflict of Interest
- 1.Lanzkowsky P. Iron deficiency anemia. In: Lanzkowsky P, Lipton JM, Fish JD, editors. Lanzkowsky Manual of Pediatric Hematology and Oncology, 6th ed. London: Elsevier; 2016. p. 32–41.Google Scholar
- 2.Verma N, Naseem S. Hypochromic anemia: iron deficiency anemia and sideroblastic anemia. In: Saxena R, editor. Gruchy’s Clinical Haemotology in Medical Practice, 6th adapted ed. New Delhi: Wiley; 2014. p. 33–57.Google Scholar
- 3.Sills R. Iron deficiency anemia. In: Behrman RE, editor. Nelson Textbook of Paediatrics, Vol. II, First South Asia Edition (Reprint 20th ed). New Delhi: Elsevier; 2016. p. 2323–6.Google Scholar
- 4.Niranjan S. Nutritional anemias in infancy and childhood. In: Parthasarathy A, editor. IAP Textbook of Pediatrics, 6th ed. New Delhi: Jaypee Brother’s Medical Publishers; 2016. p. 749–834.Google Scholar
- 5.Geisser P, Müller A. Iron pharmacokinetics after administration of ferric-hydroxide polymaltose complex in rats. Arzneimittelforschung. 1984;34:1560–9.Google Scholar
- 6.Svoboda M, Ficek R, Drábek J. Evaluation of the efficacy of iron polymaltose complex in the prevention of anaemia in piglets. Bull Vet Inst Pulawy. 2008;52:119–23.Google Scholar
- 7.Jaiswar DR, Amin PD. Solid-state characterization of ferrous ascorbate. Int J Pharm Pharm Sci. 2012;4:282–7.Google Scholar
- 9.Bopche AV, Dwivedi R, Mishra R, Patel GS. Ferrous sulphate versus iron polymaltose complex for treatment of iron deficiency anemia in children. Indian Pediatr. 2009;46:883–5.Google Scholar
- 10.Devaki PB, Chandra RK, Geisser P. Effect of oral supplementation with iron (III)-hydroxide polymaltose complex on the immunological profile of adolescents with varying iron status. Arzneimittel-Forschung. 2007;57:417–25.Google Scholar
- 11.Marwat IU, Hassan KA, Javed T, Chishti AL. Comparison of the efficacy of ferrous and iron polymaltose salts in the treatment of childhood iron deficiency anemia. Annals Kemu. 2013;19:322–6.Google Scholar
- 13.Afzal M, Qureshi SM, Lutafullah M, Iqbal M, Sultan M, Khan SA. Comparative study of efficacy, tolerability and compliance of oral iron preparations (iron edetate, iron polymaltose complex) and intramuscular iron sorbitol in iron deficiency anaemia in children. J Pak Med Assoc. 2009;59:764–8.Google Scholar
- 14.Vetter W, Steurer J. Single-centre, open, randomised, parallel-group study comparing the efficacy and tolerability of oral ferric polymaltose complex in doses of 200 mg, 400 mg and 600 mg per day. Clinical Report [internal report]. St. Gallen, Switzerland: Vifor (International) Inc; 2000.Google Scholar
- 16.Guinea JM. Results of preoperative autotransfusion with ferrous ascorbate prophylaxis in orthopedic surgery patients. Sangre (Barc). 1996;41:25–8.Google Scholar